New Video: VITROCELL® Cloud α – for Aerosol Research and Cell Exposure at the Air/Liquid Interface (ALI)

The VITROCELL® Cloud Alpha series is our newest innovation and presents a great leap forward in automated exposure of cell cultures. It combines reliable exposure of cell cultures from the respiratory tract with ease of use. This series is our new take on the well-known and frequently published VITROCELL® Cloud systems (6-, 12- and 24-well). […]

continue reading

VITROCELL® Cloud Alpha 96

The VITROCELL® Cloud Alpha 96 is our newest innovation and presents a great leap forward in automated exposure of cell cultures. It combines high throughput testing with ease of use. The development is based on the well-known and frequently published VITROCELL® Cloud formats (6-, 12- and 24-well). It’s functionality enables fully automated processes with an […]

continue reading

VITROCELL® holder systems for e-cigarettes

New designs of electronic cigarettes such as ENDS (Electronic Nicotine Delivery Systems) products or HTP (Heated Tobacco Products) lead to a large variety of different shapes which make the insertion into conventional holders with labyrinth seals impossible. VITROCELL® has developed a new holder system which is flexible to adjust to different shapes. Thus, all e-cigarettes can […]

continue reading

VITROCELL® TEM Grid holders for dose determination of airborne particles during in vitro Exposure at the air / liquid interface

. Background The assessment of toxicological effects of airborne particles to the human organism is of major importance in disease research. The presence of nano and ultrafine particles can be found both in indoor and outdoor atmospheres which include workplaces and living areas. Over the last years, the degree of contribution to diseases of such […]

continue reading

Screening antiviraler pharmazeutischer Leitwirkstoffe gegen das Coronavirus (COVID-19 / SARS-CoV-2)

In der Inhalationstherapie werden pharmazeutische Präparate als Aerosole auf Zellen des Atemtraktes im Nasen- oder Lungenbereich appliziert. Zur präklinischen Entwicklung neuer Arzneimittel werden dafür oft kommerziell erhältliche, physiologisch relevante in vitro Zellkulturmodelle des Nasen-, Rachen- oder Lungenepithels verwendet. In jüngster Zeit wurden diese Modelle verfeinert, um SARS-CoV-2 Infektionen nachzuahmen. Bei der Entwicklung  neuer Arzneimittel war […]

continue reading